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COPD outcomesAbstract Background: Evidence is increasing that suggests an expanded role of vitamin D in
health outcomes apart from its classic actions on the bone and calcium homeostasis. Vitamin D
deﬁciency has been associated with some chronic respiratory illnesses; one of them is chronic
obstructive pulmonary disease (COPD).
Objective: This study was designed to detect vitamin D level among stable COPD patients. The
effect of vitamin D supplements (200,000 IU monthly for 6 months) with regular therapy of COPD
on COPD outcomes was also evaluated.
Patients and methods: Pulmonary function test (PFT), COPD assessment test (CAT), 6 min walk
test (6MWT), serum 25-hydroxyvitamin D (25-OHD) and ionized calcium were performed on 61
COPD patients (50 males and 11 females, mean age 61.1 years). PFT and clinical assessment were
carried out at the start and completion of 6 month treatment among those with vitamin D deﬁ-
ciency. Twenty healthy age-matched and sex matched volunteers were also studied as a control
group.
Results: The distribution of vitamin D status including vitamin D deﬁciency, vitamin D insufﬁ-
ciency and vitamin D sufﬁciency was 16.4%, 34.4% and 49.2% respectively among COPD patients.
There was no signiﬁcant improvement of 6MWT, CAT score and PFT among those treated with
vitamin D supplements in addition to standard therapy of COPD.
Conclusion: Low serum level of vitamin D was less common among COPD patients than other
studies and correlates with severity of COPD. 6 month supplementation of standard treatment with
200,000 IU monthly of vitamin D did not provide additional clinical beneﬁt among COPD patients.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Introduction
Cholecalciferol (vitamin D3) is synthesized upon exposure of
the skin to (ultraviolet) UV radiation resulting in the conver-
sion of endogenous 7-dehydrocholesterol to previtamin D3,
which isomerizes to vitamin D3. To a lesser extent, vitamin
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products and cereals, oily ﬁsh and ﬁsh liver oils [1]. Synthesized
or dietary vitamin D, from the skin and the gut, respectively,
are hydroxylated in the liver to form 25-hydroxyvitamin D
[25-OHD] through the action of cytochrome P450 enzymes),
which is converted to the biologically active form of vitamin
D, 1,25-dihydroxyvitamin D [1,25(OH)2D], in the kidney
and other tissues by the 1a-hydroxylase [2].
The concentration of 25-hydroxyvitamin D in blood is
regarded as the best indicator of vitamin D status, because it
is quantitatively related to the supply of vitamin D over the
weeks preceding blood sample collection. The concentration
of 25-OHD reﬂects the supply of vitamin D from both the diet
and from cutaneous synthesis under the inﬂuence of solar
ultraviolet light [3].
Conventionally, vitamin D is known for its actions in bone
mineralization and calcium homeostasis. Some studies have
highlighted the role of vitamin D, vitamin D receptor (VDR)
in regulation of several genes involved in inﬂammation, immu-
nity, cellular proliferation, differentiation, and apoptosis. So,
vitamin D may play a role in multiple chronic diseases such
as cancer, autoimmune diseases, infections, and cardiovascular
disorders [4,5].
Vitamin D may also have a role in several diseases involving
the respiratory system such as asthma, chronic obstructive pul-
monary disease, cystic ﬁbrosis, and respiratory infections.
These studies have demonstrated a high prevalence of vitamin
D deﬁciency in their participants [6–9]. Patients with chronic
obstructive pulmonary disease have a high prevalence of vita-
min D deﬁciency, ranging from approximately 30% in mild
COPD to over 75% in severe COPD [9–11]. Particularly for
COPD, vitamin D deﬁciency may enhance chronic airway and
systemic inﬂammation, reduce bacterial clearance, and increase
the risk for infectious exacerbations at the same time [12].
Some intervention studies are being undertaken to study
the impact of adequate vitamin D supplementation in chronic
diseases. COPD is a candidate disease for which vitamin D
supplementation might be beneﬁcial. Epidemiological studies
revealed a dose-dependent association between serum
25-OHD levels and pulmonary function so that adequate vita-
min D supplementation may extend beyond its protection
against osteoporotic fractures. In line with the novel insights
into the immune function of vitamin D, it is tempting to spec-
ulate that vitamin D may down-regulate the inﬂammatory
immune response in the airways while boosting innate immune
defense against different microorganisms. Apart from its
effects on osteoporosis, vitamin D may also interfere with
other comorbidities of COPD such as skeletal muscle weak-
ness, cardiovascular disease, and cancer. Because respiratory
treatments in COPD fail to reverse disease progression,
interventional trials that may exploit the broader potential of
vitamin D are warranted [12].
Aim of the work
We undertook this study to assess serum level of vitamin D
among patients with stable COPD. In addition the role of sup-
plementation of vitamin D (200,000 IU cholecalciferol per
month for 6 months) among COPD patients with vitamin Ddeﬁciency plus standard therapy of COPD on exercise capac-
ity, clinical response and spirometry was assessed.
Patients and methods
Sixty-one cases of stable COPD were recruited from those
attending the outpatient chest clinic at Minia University hospi-
tal from January 2011 to December 2013. The study also
included 20 healthy controls.
This study was approved by the ethics committee of Faculty
of Medicine, Minia University and consent was obtained from
patients and controls.
Patients were diagnosed according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
deﬁnition (postbronchodilator FEV1/FVC ratio <0.7). Sta-
ble COPD was deﬁned by the lack of hospitalizations,
urgent care visits, antibiotics, or changes in medications
within 4 weeks prior to study. Patients were excluded if they
had a past history of TB, asthma, active cancer, diabetes,
hypertension, ischemic heart disease, chronic kidney disease,
liver failure, history of upper or lower respiratory tract
infections or use of oral steroid within 1 month prior to
study, as all these conditions are associated with a low
serum level of vitamin D [4].
All the patients and healthy controls had been subjected to
the following:
- Full detailed history taking including (age, sex, smoking
status, patient’s medications, CAT score and GOLD stage).
- Clinical examination, body mass index (BMI), and 6 min
walk test were also determined and 6 min walk distance
(6MWD) was detected.
- Local chest examination.
- Investigations included:
1. Plain chest X-ray (PA view).
2. Complete blood count was done by automated cell
counter (Sysmex KX 21N, Cole, Japan).
3. The liver, renal function tests and random blood sugar
were determined using Flexor 200ELI, Tech, France
apparatus.
4. Serum ionized calcium (Ca) was determined by ion
selective electrode (AVL, USA).
5. Electrocardiogram (ECG).
6. Pulmonary function tests (PFTs) using 2130 spirometer
(Vmax, Sensormedics, USA), which was calibrated
daily. Patient’s maximum effort had been used in per-
forming the test so as to avoid any expected error in
diagnosis. Results were obtained for forced vital capac-
ity (FVC), forced expiratory volume in 1st second
(FEV1), and FEV1/FVC percentage. Subjects who
had FEV1/FVC <70% underwent post – bronchodila-
tor spirometry test, 20 min following 2 puffs of salbuta-
mol 200 mcg.
7. Blood samples were collected, centrifuged within 2 h
of sampling, and the serum was frozen and stored at
40 C until analyzed for measurement of serum
25-hydroxyvitamin D (25-OHD) by enzyme immuno-
assay kits supplied by Immunodiagnostic AG,
Germany.
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- This test kit is a competitive protein binding assay for the
measurement of 25-OH Vit D. It is based on competition
of 25-OH Vit D present in the sample with 25-OH Vit D
tracer, for the binding pocket of vitamin D binding protein
(VDBP, Gc-globulin). Since all circulating 25-OH Vit D is
bound to VDBP in vivo, samples have to be precipitated
with precipitation reagent to extract the analyte.
- 25-OH Vit D present in the sample competes with the
tracer, coated on the well for the speciﬁc binding site of
the binding protein and the VDBP-antibody is bound to
the vitamin binding protein. Hence, with increasing
concentrations of 25-OH Vit D in the sample, the amount
of binding protein immobilized to the well via the tracer,
is reduced. After a washing step to remove unbound
components, the quantitation of VDBP is achieved by incu-
bation with a host speciﬁc peroxidase labeled antibody
using TMB (tetramethylbenzidine) as enzyme substrate.
An acidic stopping solution is then added to stop the
reaction. The color converts to yellow. The intensity of
the yellow color is indirectly proportional to the concentra-
tion of 25-OH Vit D in the sample.
According to Endocrine Society Clinical Practice
Guidelines, vitamin D deﬁciency is deﬁned by most experts
[13–15] as a 25-hydroxyvitamin D level of less than 20 ng per
milliliter (50 nmol per liter). A level of 25-hydroxyvitamin D
of 21–29 ng per milliliter (52–72 nmol per liter) can be consid-
ered to indicate an insufﬁciency of vitamin D, and a level of
30 ng per milliliter or greater (>75 nmol per liter) can be con-
sidered to indicate sufﬁcient vitamin D.
According to this level of vitamin D, 61 COPD patients
were divided into the following groups:
Group (A): Included 31 COPD patients who had an
impaired vitamin D level, 10 of them had vitamin D deﬁ-
ciency and 21 had vitamin D insufﬁciency.
Group (B): Included 30 COPD patients with a sufﬁcient
level of vitamin D.
Control group (group C): Included 20 apparently healthy
individuals matched in age and sex with the other 2 groups
and their serum level of 25-OHD was >30 ng/ml.
Those with vitamin D deﬁciency received their usual treat-
ment of COPD supplemented with a high-dose of vitamin D
(cholecalciferol 200,000 IU ampoule) intramuscular injection
every 4 weeks for 6 months. The outcome parameters used
for the study after 6 months were spirometry, 6MWT and
CAT score. Serum ionized calcium level at the end of 6 months
was re-assessed among 10 patients who received vitamin D
supplements to detect if any of them developed hypercalcemia
as a sign of vitamin D overdose. None of these patients devel-
oped hypercalcemia.
Statistical analysis
Data entry and analysis were all done using the software SPSS
version 13. Quantitative data were presented by mean and
standard deviation; qualitative data were presented as
frequency distribution. A one way ANOVA, Student’s t-test,correlation and chi square tests were used. Correlation was
done using Pearson correlation. A value of P< 0.05 was con-
sidered to be statistically signiﬁcant.
Results
Table 1 shows the general characteristics of all studied groups,
it was found that there was a signiﬁcant difference in smoking
and mean pack-year among COPD patients (groups A & B)
and the control group (group C) (P= 0.03 and 0.01 respec-
tively). Considering BMI, there was no signiﬁcant difference
in BMI among all of the COPD patients and healthy controls
(P= 0.7). There was a signiﬁcant difference in 6MWD, post-
bronchodilator values of FVC%, FEV1% and FEV1/FVC
among COPD patients and the control group (P= 0.001).
Besides, FVC% predicted and FEV1% predicted were signiﬁ-
cantly lower in the group A than the group B (P= 0.01 and
0.03 respectively). It was found that those with impaired vita-
min D level (group A) had a signiﬁcantly higher CAT score
and GOLD stage than those with sufﬁcient level of vitamin
D (group B) (P= 0.004 and 0.04 respectively).
Fig. 1 shows mean 25-hydroyvitamin D and ionized cal-
cium levels among the studied groups. It was found that 10
COPD patients out of 31 in the group A had vitamin D deﬁ-
ciency with a mean value of 12.0 ± 4.5 ng/ml and the remain-
ing 21 had vitamin D insufﬁciency with a mean value of
24.4 ± 3.7 ng/ml. The difference of 25-OHD mean value
between the group A (20.4 ± 6.6) and both of the group B
(47.1 ± 18.8) and group C (44.4 ± 9.1) was signiﬁcant
(P= 0.001). In addition, the mean value of serum ionized cal-
cium was signiﬁcantly lower among the group A (0.79 ± 0.1)
versus groups B and C (0.9 ± 0.1 & 1.1 ± 0.05 respectively)
(P= 0.01).
It was found that there was a signiﬁcant positive correlation
between serum 25-OHD and FVC% predicted, FEV1% pre-
dicted, FEV1/FVC and GOLD stage and a negative correla-
tion with CAT score among patients with COPD. On the
other hand, there was no correlation between both of clinical
variables and pulmonary function test among the control
group (Table 2 and Fig. 2).
Table 3 shows that in spite of minor improvement in CAT
score, 6MWD, FVC% predicted and FEV1% predicted, this
improvement was not statistically signiﬁcant (P> 0.05 in all
of them).
Discussion
Vitamin D deﬁciency is more common than previously
thought. The Centers for Disease Control and Prevention
has reported that the percentage of adults achieving vitamin
D sufﬁciency as deﬁned by 25-OHD of at least 30 ng/mL has
declined from about 60% in 1988–1994 to approximately
30% in 2001–2004 in whites and from about 10% to approxi-
mately 5% in African Americans during this same time. So
hypovitaminosis D is as an important public health problem
in the United States and worldwide [16].
Few studies have assessed the relevance of vitamin D deﬁ-
ciency in COPD by measuring serum levels of 25-hydroxyvita-
min D which is the principal circulating vitamin D metabolite
and recognized as the best short-term biomarker of total expo-
sure to vitamin D [17].
Table 1 Descriptive data of the studied groups.
Character Group A
No. = 31
Group B
No. = 30
Group C
No. = 20
P
Age 59.9 ± 8.1 62.3 ± 7.2 56.1 ± 8.17 0.075
Sex
Male 23 (74.2%) 27 (90%) 16 (80%) 0.2
Female 8 (25.8%) 3 (10%) 4 (20%)
Smoking
Current smoker 10 (32.3%) 10 (33.3%) 4 (20%) 0.03
Ex smoker 12 (38.7%) 16 (53.3%) 5 (25%)
Non smoker 9 (29%) 4 (13.3%) 11 (55%)
Pack-year 21 ± 4.5 28.8 ± 10.2 16.2 ± 4.7 0.01
BMI 24.1 ± 4.9 23.2 ± 4.1 23.8 ± 1.6 0.7
Medications
ICS + short acting B2 agonist 19 (61.3%) 17 (56.7%) – 0.4
Short acting B2 agonist 6 (19.5%) 0
Long acting B2 agonist 3 (9.6%) 0
Theophylline + short acting B2 agonist 3 (9.6%) 13 (43.3%) 0.001
6MWD (meter) 266.8 ± 93.8 272.4 ± 133.1 384.7 ± 53.1 0.001
FVC% pred. 56.1 ± 17.9 68.6 ± 10.5 85.1 ± 4.6 0.001
FEV1% pred. 33.7 ± 10.8 40.8 ± 13.6 83.1 ± 3.7 0.001
FEV1/FVC 46.7 ± 12.7 50.7 ± 8.3 74.7 ± 2.1 0.001
CAT score 26.2 ± 5.1 22.6 ± 4.4 – 0.004
GOLD stage 3.1 ± 0.6 2.8 ± 0.6 – 0.04
Data are represented as number and percentages or mean ± SD, P< 0.05 = signiﬁcant.
ICS = inhaled corticosteroids.
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Figure 1 Serum level of 25-OHD and ionized calcium among all
the studied groups.
Table 2 Correlation coefﬁcient between serum 25-OHD and
clinical data among all of the studied groups.
Variable COPD groups Control group
r P r P
Age 0.01 0.8 0.18 0.4
BMI 0.01 0.6 0.01 0.9
6MWD 0.10 0.4 0.15 0.5
FVC% pred. 0.61 0.001 0.1 0.6
FEV1% pred. 0.79 0.008 0.09 0.6
FEV1/FVC 0.61 0.001 0.05 0.8
GOLD stage 0.80 0.05 – –
CAT score 0.24 0.04 – –
r=0.61       p=0.001
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Figure 2 Correlation coefﬁcient between serum 25-OHD and
FVC% predicted among COPD patients.
Table 3 Comparison of clinical variables and pulmonary
function test before and after 6 months of vitamin D supple-
ments among patients with vitamin D deﬁciency.
Character Before therapy After therapy P
CAT score 25.5 ± 6.4 24.9 ± 7.7 0.08
6MWD 260.4 ± 116.4 284.8 ± 71.4 0.3
FEV1% pred. 32.4 ± 14.1 33.5 ± 17.2 0.1
FVC% pred. 55.9 ± 10.4 56.4 ± 15.6 0.4
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level among stable COPD patients. It was found that vitamin
D was impaired among 50.8% of the studied COPD patients,
16.4% of them had vitamin D deﬁciency and 34.4% had vita-
min D insufﬁciency.
Forli et al. [18] reported that in a small sample of patients
with advanced COPD awaiting lung transplantation, the
majority (>50%) suffered from vitamin D deﬁciency (25-
OHD <20 ng/ml). In an outpatient study on patients with
COPD in Denmark, 68% of the participants had osteoporosis
or osteopenia [19].
The cause of lower percentage of vitamin D deﬁciency in
our study than these reported studies could be attributed to
the fact that most of the studied patients with vitamin D deﬁ-
ciency are farmers exposed to the sun most of the day and milk
and cheese are main constitutes of daily foods.
Impaired vitamin D in COPD can be due to that patients
with COPD suffered from reduction of outdoor activity, a
reduced capacity of aging skin for vitamin D synthesis, a lower
food intake, increased glucocorticoids-induced catabolism,
impaired activation as a consequence of renal dysfunction,
and a lower storage capacity in muscle and fat due to wasting
[12]. Franco et al. [20] found that patients with COPD, even
without chronic use of systemic glucocorticoids, have
increased risk for osteoporosis and low levels of vitamin D,
which is correlated with the severity of disease.
Regarding correlation of vitamin D with other clinical vari-
ables, the present study showed that serum 25-OHD correlated
signiﬁcantly in a positive direction with pulmonary function
test parameters among COPD patients, while there was no cor-
relation among healthy controls. On the other hand, 25-OHD
correlated negatively with CAT score. This ﬁnding was in
accordance with Janssens et al. [9] who found that 25-OHD
serum levels were correlated signiﬁcantly with FEV1 in the
COPD subgroup (r= 0.28, P< 0.0001) with no correlation
with FEV1 in the subgroup of healthy controls. EL-Shafey
and EL-Srougy [21] found also that a signiﬁcant correlation
was found between serum 25-OHD and FEV1 (r= 0.896,
P= 0.001).
However, another study reported by Shaheen et al. [22] in
an older adult UK population (the Hertfordshire Cohort
study) did not show a positive correlation between serum
25(OH)D concentrations and lung function in spirometrically
deﬁned COPD patients. This study concluded that vitamin D
is not an important determinant of adult lung function in
COPD.
The mechanisms by which vitamin D levels might affect
lung function are unclear. Potential explanations could depend
on the calcemic effects of vitamin D. The vital capacity and
total lung capacity were found to decline with an increasing
number of thoracic vertebral fractures as a direct consequence
of vitamin D deﬁciency [23]. Kyphosis related to osteoporosis
caused limitation in rib mobility and inspiratory muscle func-
tion and correlated with a reduction in FEV1 and FVC [24].
The altered properties of the thoracic skeleton could result in
failure of the respiratory muscles contributing to the patho-
physiology of COPD.
An important systemic consequence of COPD is muscle
weakness, and this is associated with an increased risk of
mortality.
Vitamin D plays a role in inﬂuencing skeletal muscle func-
tion, with deﬁciency resulting in muscle weakness, and VDRsare present in the muscles [25]. It has been reported that poly-
morphisms in the VDR can inﬂuence muscle weakness in both
healthy individuals and patients with COPD [26], suggesting
that the VDR has a signiﬁcant inﬂuence on one of the impor-
tant complications of this disease.
Vitamin D may also interact with stress, tobacco smoke,
and air pollutants through an oxidative/antioxidative imbal-
ance, inﬂuencing lung inﬂammation and consequently lung
function [27] .
Chronic obstructive pulmonary disease is a progressive and
disabling disorder. Unfortunately, the treatment, mostly com-
prising bronchodilators of different groups, is entirely symp-
tomatic. Findings of some epidemiological observations
demonstrating beneﬁts with dietary supplements and some
vitamins have therefore raised the hope of managing COPD
with an additional approach to currently available therapy
[28–31].
Vitamin D therapy in COPD is an intriguing consideration.
Given that vitamin D is inexpensive and safe, it would be a
desirable treatment option if proven to be effective [32]. In
addition to preserving skeletal health, vitamin D may have
other health beneﬁts, including improving both respiratory
muscle and skeletal muscle function.
Vitamin D may play a beneﬁcial role in improving the
innate immune system against chronic respiratory infections
by up-regulating speciﬁc antimicrobial peptides (human cath-
elicidin antimicrobial peptide (hCAP-18) [33]. In addition, a
meta-analysis of randomized controlled trials concluded that
use of vitamin D supplements is associated with a decrease
in total mortality rates [34].
The second aim of the present study was to evaluate the
effect of vitamin D supplements in addition to the regular
therapy among COPD patients. Unfortunately, pulmonary
function test, exercise capacity as evidenced by 6MWD, and
CAT score did not improve signiﬁcantly after 6 months among
COPD patients who took vitamin D supplements. This lack of
clinical improvement could be attributed to the fact that, the
studied COPD patients who took vitamin D supplements
had a severe airﬂow limitation as their mean post-bronchodila-
tor FEV1% predicted was 33.7 ± 10.8, in addition their CAT
score was >10 and they had a severe COPD stage (GOLD
stage = 3.1 ± 0.6). Intervention in the earlier stages of COPD
might therefore be more effective, which is consistent with the
idea that such milder stages are also more sensitive to disease
modiﬁcation [35].
There are limited studies on the use of vitamin D supple-
ments in COPD patients, one study [36] evaluated a monthly
dose of 100,000 IU of vitamin D for 1 year in addition to reg-
ular therapy among COPD patients and they found that addi-
tion of vitamin D did not reduce the time to ﬁrst exacerbation
or the rate of exacerbations in patients with moderate to very
severe COPD. Secondary outcomes in the same study, such as
FEV1, quality of life, and death, were also not affected. How-
ever, a post hoc analysis in 30 participants with severe vitamin
D deﬁciency (serum 25-[OH]D levels <10 ng/mL) at baseline
showed a signiﬁcant reduction in exacerbations in the vitamin
D group (rate ratio, 0.57 [CI, 0.33–0.98]; P= 0.042).
In conclusion, our study revealed that hypovitaminosis D
was less common than western studies among stable COPD
patients. We also found a direct relationship between serum
level of vitamin D and pulmonary function test parameters.
The long term use of vitamin D supplements in addition to
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outcomes.
We recommend further studies to assess vitamin D level
among a bigger number of COPD patients and to judge on
the use of vitamin D supplements on a large sample size than
the current one. Finally, we recommend comparing COPD
outcomes in vitamin D sufﬁcient patients who take usual treat-
ment of COPD versus those with vitamin D deﬁciency and on
vitamin D supplements to detect the usual progress of the
disease.Conﬂict of interest
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